Moxo / Neurotech Solutions

Cutting edge Cloud based technologies focused on human cognition and behavior with a special emphasis on Attentional disorders

Eliminating undiagnosed ADHD is our mission.

Helping every person with ADHD improve their quality of life and fulfil their potential is our passion.

About Us

We strive to provide advanced solutions to help improve people’s everyday
functioning, well-being, academic abilities and achievements.
Neurotech Solutions is a leader in the area of attention with an expertise in attentional profiling and analytics. The company enjoys significant success with its MOXO tool for ADHD diagnosis already clinically adopted by numerous clinicians across the globe. Neurotech is highly engaged in innovative developments in these areas and strive to provide advanced solutions to help improve people’s everyday functioning, well-being, academic abilities and achievements.
Our Credo

I make my dreams a reality, fulfilling myself by continuous learning and exploration in order to become best at what I do. I act without ego, a positive thinker advocating solutions and actions. I am passionate about my work, my ability to contribute to society by improving patient’s lives. I am accountable for my actions and know that my coworkers will support me in my time of need, as I will support them. I am result orientated and loved to exceed expectations, I am MOXONESS.

Our customers
Our customers are the reason we continue to exist. We make it our mission to bring forth best in class products that are scientifically credible, deliver substantial added value above existing technologies, and will make their user experience effective, fun, and easy to use. We take it on ourselves to continue to surprise our customers with new and integrative ways of thinking about ADHD, suited for their individual needs.
Our Mission
Our mission is to help people who struggle with ADHD improve their quality of life and fulfil their potential. To that end, we transform clinical knowledge into insightful diagnostic tools, innovative treatment programs and efficient monitoring systems.

Our Products

MOXO

MOXOd-CPT – The only fully online, cloud based validated CPT today was found to be highly effective in the measurement of Attentiveness, Impulsiveness, Timeliness and Hyper-reactivity, but it is due to the unique distractor system employed by the test that assisted to its quickly gaining popularity.
MOXO utilizes current and updated norm pool, containing over 900 international norms.

MOXOedu

The MOXOedu brings the clinically proven MOXO engine to the learning domain. Aimed for all students and learners, its short 20-min cloud based assessment creates an attentional profile of the individual student, the entire class or other grouping. Moreover, MOXOedu provides concrete evidence to support the educational team’s professional approach; to better understand student needs and facilitate parent-teacher communication about their child’s learning habits and attentional challenges.

For educators seeking to develop and deploy Social-Emotional Learning programs, MOXOedu™ assesses each learner’s cognitive attentional profile, to provide invaluable data for adaptive personal learning and cognitive development. Thus improving learners’ everyday functioning, well-being, academic abilities and achievements.

Awards and prizes

Israel Innovation
Authority IIA

Awarded a monetary prize to research development plan for improve processes in governmental offices. Machine learning bases on our data to predict the right medication and dosage – Personalisation of ADHD medication

SMEi phase 1 -
Horizon 2020 EU

Prize awarded for a business feasibility study – for Seemee mobile, self-assessment application for screening ADHD, utilizing CPT and event tracking

1st prize - Harel insurance with Tokio Marine

Technological solution for insurance companies recommending preventative measure for decreasing car accidents by screening young ADHD drivers for attentiveness influences of driving.

Top 10 of South summit
Innovation is business contest

presentation in the Summit – Seemobile, mobile based screening tool for ADHD utilizing CPT and eyetracking as a biomarker

Advisory Board

We see our board members as visionaries they invested in a company that plans to share the world of ADHD. We are committed to our shareholders to excel in all performance, pushing forward boundaries of possibility, maximizing resources utilization by doing more with less, and rigorously expanding our activities worldwide. By doing this, we will create an excellent return on investment for our shareholders and create a sustainable profitable business.
Dr.
Jacob (Yaki) Dayan

CEO

 Dr. Dayan is an EdTech visionary, ecosystem builder, and a recognized expert in education innovation and entrepreneurship. Dr. Dayan founded EdTech Israel in 2014 with the vision to transform startup-nation to EdTech-nation.

EdTech Israel is a nationwide, unbiased, independent social impact business that successfully connects the Israeli ecosystem with international markets. 

Dr. Dayan is also the CEO of Neurotech Solutions . With expertise in attentional profiling and analytics, Neurotech Solutions is a new leader in the field of attention. For the education and learning sectors, Neurotech is the industry’s first cloud-based assessment available for the attention profiling of students and learners. 

 

Dr. Dayan holds a BSc in Electronics Engineering from the well-renowned Technion in Haifa (1982), and a PhD in Education from the University of Haifa (2014).

Prof.
César Soutullo, MD,

Scientific Board

Prof. César Soutullo is Professor of Psychiatry and Director of ADHD Outpatient Program at The University of Texas Health Science Center in Houston, Texas, USA, McGovern Medical School, at the Louis A. Faillace MD Department of Psychiatry and Behavioral Sciences. 

He moved there in 2019, after working 20 years as Director of the Child & Adolescent Psychiatry (CAP) Unit, and Training Director of the CAP Fellowship program at the University of Navarra Clinic, in Pamplona, Spain.

 

Prof. Soutullo graduated from the Complutense University of Madrid College of Medicine, Spain. After two years of general training (Intern al Medicine, Surgery & Emergency Medicine) in the U.K., he completed his Residency in Psychiatry, and Fellowships in Biological Psychiatry and Child & Adolescent Psychiatry at the University of Cincinnati, Ohio, USA., where he then was Assistant Professor in Clinical Psychiatry.

He completed his PhD at the University of Navarra (2002), in Psychiatry & Neurosciences and his dissertation on Phenomenology of Children at High Risk for Bipolar Disorder obtained the “Extraordinary Thesis Award”.

He received awards such as the AACAP Presidential Scholar Award, the Association for Academic Psychiatry Bristol-Myers Fellowship in Academic Psychiatry, and the Society of Biological Psychiatry Eli Lilly Fellowship Award, and has been Mentor twice in the Donald J. Cohen Fellowship.

His main research interests are ADHD, pediatric mood disorders (especially bipolar), and pediatric psychopharmacology, with research funding from national and international private and public sources. He is member of EUNETHYDIS´ Guidelines Group and of the Scientific Program Committee of the World Federation of ADHD.

Prof. Soutullo is a reviewer of 29 international journals, and is author of 98 original reports, 108 book chapters, 241 abstracts at national or international conferences and has authored or edited 22 books (H Factor: 28), and has been invited to give hundreds of talks at National and international conferences/meetings/courses.

Sam Goldstein
Sam Goldstein

Scientific Board

Sam Goldstein, PhD is an Adjunct Assistant Professor at the University of Utah School of Medicine. He currently serves as Editor-in-Chief of the Journal of Attention Disorders and sits on the editorial boards of 6 peer reviewed journals.

 

Dr. Goldstein has authored over 50 trade and science texts as well as over 36 science-based book chapters and 30 peer reviewed research articles. He has also co-authored ten psychological tests.

 

He is the Clinical Director of the Neurology Learning and Behavior Center. The center conducts evaluations, consultation and provides treatment services to 300 individuals and families each year. 

He is co-editor of the Encyclopedia of Child Development. Recent books include the Handbook of Intelligence: Evolutionary Theory, Historical Perspective and Current Concepts, Handbook of Resilience – 2nd Edition, Raising Resilient Children with Autism Spectrum Disorders, Handbooks of Neurodevelopmental and Genetic Disorders in Children and Adults, Assessment of Intelligence and Achievement, Assessment of Autism Spectrum Disorders, Handbook of Executive Functioning, Assessment of Impairment and Managing Children’s Classroom Behavior: Creating Sustainable Resilient Classrooms. He is the co-author of the Autism Spectrum Rating Scales, Comprehensive Executive Functioning Inventory, Rating Scales of Impairment and the Cognitive Assessment System Second Edition.

He has lectured to thousands of professionals and the lay public in the U.S., South America, Asia, Australia and Europe.

Our Team

Our employees are part of our family. We encourage our employees to make a difference in society by taking a personal interest in what the company is engaged with. We listen to our employees, valuing the contribution each employee brings to the table, and their unique perspective on things. We nourish effective cross-function teamwork that plans well, engage in innovative thinking processes and executes to target. We want our employees to smile on their way to work to feel appreciated, to be well remunerated and to passionately give their heart and mind to the organization.
Ohad Lavi

CEO

I’m a father to two children with ADHD. They are both amazing, each in their own unique way. Neurotech allows me to gradually change their world and the way they are perceived by others.
Amit Foox

V.P. Sales

Over fifteen years of experience in building commercial and marketing strategy and developing new business channels. Previously, Director of Sales and Marketing at Hospitech Respiration.
Roni Bochman-Ronen

Marketing Director

I am passionate about all things marketing related. But having a good and worthy product to work with brings gratification and a sense of purpose to life. Working with Neurotech solutions’ MOXO is just that kind of product. I feel I am doing something good for someone where in the world everyday.
Aviram Salomon

Product & Regulatory Director

For me Neurotech is my second house. After 11 years and still counting in the company I know that we make positive change in the field of ADHD and actually effect on the life of our end users. I am proud to be the product manager of MOXO.
Noa Kezurer

Product and Innovation Director

Elena Ivchenko

Success Engineer

Megi Franko

HR, Administration Manager

I am the office manager at Neurotech Solutions, and have many years of experience at employee management, procurement, accounting and sales. I support all training and sales process in Israel and abroad for MOXO, and help administer tests.

I Love my work. The MOXO team and the MOXO test.

2021 Ⓒ Neurotech Solutions Ltd.
Ver: 201609 | ISO 13485:2016 certified

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 877041

In the United States ONLY, MOXO™ d-CPT should be used for cognitive assessment of attention and executive functions, and is not indicated for ADHD diagnosis

UX/UI Three Bears            Development Site-Pro